Meeting
2013 ASCO Annual Meeting
A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.
Authors
Richard S. Finn
University of California, Los Angeles, Geffen School of Medicine, Los Angeles, CA
Richard S. Finn , Veronique Dieras , Karen A. Gelmon , Nadia Harbeck , Stephen E. Jones , Maria Koehler , Miguel Martin , Hope S. Rugo , Seock-Ah Im , Masakazu Toi , Eric Roland Gauthier , Xin Huang , Sophia Randolph , Dennis J. Slamon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01740427
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS652)
DOI
10.1200/jco.2013.31.15_suppl.tps652
Abstract #
TPS652
Poster Bd #
15C
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
First Author: Dennis J. Slamon
Poster
2015 ASCO Annual Meeting
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
First Author: Richard S. Finn
Poster
2015 ASCO Annual Meeting
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
First Author: John Crown
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira